South Korea
· Delayed Price · Currency is KRW D&D Pharmatech Statistics
Total Valuation
D&D Pharmatech has a market cap or net worth of KRW 637.08 billion. The enterprise value is 616.31 billion.
| Market Cap | 637.08B |
| Enterprise Value | 616.31B |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
D&D Pharmatech has 10.71 million shares outstanding. The number of shares has increased by 8.08% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 10.71M |
| Shares Change (YoY) | +8.08% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 20.85% |
| Owned by Institutions (%) | 7.53% |
| Float | 7.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 55.70 |
| PB Ratio | 9.16 |
| P/TBV Ratio | 17.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -21.53 |
| EV / Sales | 53.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -27.76 |
Financial Position
The company has a current ratio of 3.58, with a Debt / Equity ratio of 0.14.
| Current Ratio | 3.58 |
| Quick Ratio | 3.20 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.44 |
| Interest Coverage | -40.69 |
Financial Efficiency
Return on equity (ROE) is -47.25% and return on invested capital (ROIC) is -21.91%.
| Return on Equity (ROE) | -47.25% |
| Return on Assets (ROA) | -17.70% |
| Return on Invested Capital (ROIC) | -21.91% |
| Return on Capital Employed (ROCE) | -28.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 51,606.00 |
| 200-Day Moving Average | 44,366.50 |
| Relative Strength Index (RSI) | 62.17 |
| Average Volume (20 Days) | 364,107 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, D&D Pharmatech had revenue of KRW 11.44 billion and -28.62 billion in losses. Loss per share was -2,823.11.
| Revenue | 11.44B |
| Gross Profit | 11.42B |
| Operating Income | -25.02B |
| Pretax Income | -30.36B |
| Net Income | -28.62B |
| EBITDA | -19.49B |
| EBIT | -25.02B |
| Loss Per Share | -2,823.11 |
Balance Sheet
The company has 30.01 billion in cash and 9.78 billion in debt, giving a net cash position of 20.23 billion or 1,889.48 per share.
| Cash & Cash Equivalents | 30.01B |
| Total Debt | 9.78B |
| Net Cash | 20.23B |
| Net Cash Per Share | 1,889.48 |
| Equity (Book Value) | 69.57B |
| Book Value Per Share | 6,634.34 |
| Working Capital | 28.68B |
Cash Flow
In the last 12 months, operating cash flow was -21.80 billion and capital expenditures -395.75 million, giving a free cash flow of -22.20 billion.
| Operating Cash Flow | -21.80B |
| Capital Expenditures | -395.75M |
| Free Cash Flow | -22.20B |
| FCF Per Share | -2,073.41 |
Margins
Gross margin is 99.83%, with operating and profit margins of -218.74% and -250.27%.
| Gross Margin | 99.83% |
| Operating Margin | -218.74% |
| Pretax Margin | -265.43% |
| Profit Margin | -250.27% |
| EBITDA Margin | -170.42% |
| EBIT Margin | -218.74% |
| FCF Margin | n/a |
Dividends & Yields
D&D Pharmatech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.08% |
| Shareholder Yield | -8.08% |
| Earnings Yield | -4.49% |
| FCF Yield | -3.48% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
D&D Pharmatech has an Altman Z-Score of 3.5.
| Altman Z-Score | 3.5 |
| Piotroski F-Score | n/a |